Affordable and Effective Pharma Treatment
RMDM Pharma is the pharmaceutical wing of the RMDM Group.
It provides the third link in our comprehensive three-pronged approach to preventing, detecting and treating cancer.
Currently in the early stages, our team is conducting clinical trials for the release of a prodrug that renders current cancer treatments more effective.
Developed and patented by Dr. Johannes Coy and his team in Germany, this pro-drug – Oxybenfothiamine – hinders the activity of TKTL1 and decelerates the metabolisation of cancerous cells.
Combined with the early detection made possible by the Pantum Detect test, this affordable and effective treatment represents a paradigm shift in the treatment of cancer, allowing us to effectively fight even the most malignant and chemotherapy-resistant tumours.
Cutting-Edge Research Delivered to Local Markets
RMDM Pharma funnels this innovative research into local delivery throughout the UK and the Middle East and North Africa (MENA).
Please contact us should you like to know more about this pro-drug or if you would like to be informed of RMDM Pharma’s news and developments.
Other Resources You Might Find Useful
Scientists transform breast cancer cells from treatment-resistant into treatment-sensitive
Scientists may have found a solution to treat an aggressive, treatment-resistant type of breast cancer. A new study suggests it is possible to change an aggressive type of breast cancer into a non-aggressive type that responds well to common treatments. Scientists discovered a way to sort through the intricate genetic…
Scotland’s £10 Million Investment to Improve Cancer Care
This week we are excited to share the news of an incredible commitment to early cancer detection by the Scottish Government. A £10 million fund has been granted to improve cancer waiting times. The fund will enable the NHS in Scotland to invest in staff skills, new diagnostic tests, and…
COVID-19 Hits Breast Cancer Screenings
Breast cancer is the most common cancer in the UK, with around 12,000 women diagnosed with the condition every year. Unfortunately, this week an analysis of NHS England figures by Cancer Research UK has found that around 10,600 fewer women started treatment for breast cancer in 2020, compared to the…
Reforming Prostate Cancer Testing: Chris Hoy’s Urgent Appeal for Change
Olympic cyclist Sir Chris Hoy is advocating for improved prostate cancer tests for younger men following his terminal diagnosis in September 2023. His recent interview with the BBC reveals the limitations of the NHS’s current protocol for prostate cancer testing.
Government and Tech Innovators Unite to Advance Cancer Detection: The Potential of Pantum Detect
In a recent press release, the UK government outlined an initiative to boost tech deals aimed at further innovating cancer diagnosis in the country. This plan follows the Darzi review, which highlighted the critical state of the NHS, particularly the urgent need to improve cancer survival rates.
Darzi Report Findings: The Urgent Need for Innovative Technology in NHS Cancer Care
In the House of Commons, Health Secretary Wes Streeting introduced a "national mission" to tackle key health challenges. Presenting the Darzi report, commissioned by the Labour government, he outlined the NHS's ongoing struggles in the post-pandemic era, including missed targets in cancer care, A&E services, and hospital treatment.
The UK’s Approach to Multi-Cancer Detection Tests
Last month, the UK National Screening Committee (UK NSC) shared their updated view on Multi-Cancer Detection (MCD) tests. They highlighted the potential and the immediate need for a multi-cancer detection solution in the UK. They are working to outline a roadmap for finding this solution. At RMDM, we are at…
Why Multi-Cancer Early Detection Tests are the Future
Historically, early detection has focused on routine screenings for only a handful of cancers, such as breast, colorectal, cervical, lung, and prostate cancers. However, these screenings are not always effective. Many cancers are still detected at later stages when treatment is less effective. This challenge has motivated scientists to develop…
The Problem with the Cancer Waiting Time Crisis
Last month the BBC revealed that “cancer waiting times for 2023 in England were the worst on record”. Only 64.1% of patients started treatment within 62 days of a cancer suspicion, meaning nearly 100,000 waited longer than they should for life-saving care. These numbers are not just another statistic, they…
The Effect of TKTL1 in Breast Cancer: A Biomarker for Early Detection
Breast cancer is the second leading cause of cancer-related deaths in women. Thanks to pioneering research and diagnostic tests, we are discovering solutions to detect breast cancer early on. The TKTL1 gene, in particular, represents an incredible leap in our understanding of metabolism and cancer cell growth. In a new…
Scientists transform breast cancer cells from treatment-resistant into treatment-sensitive
Scientists may have found a solution to treat an aggressive, treatment-resistant type of breast cancer. A new study suggests it is possible to change an aggressive type of breast cancer into a non-aggressive type that responds well to common treatments. Scientists discovered a way to sort through the intricate genetic…
Scotland’s £10 Million Investment to Improve Cancer Care
This week we are excited to share the news of an incredible commitment to early cancer detection by the Scottish Government. A £10 million fund has been granted to improve cancer waiting times. The fund will enable the NHS in Scotland to invest in staff skills, new diagnostic tests, and…
COVID-19 Hits Breast Cancer Screenings
Breast cancer is the most common cancer in the UK, with around 12,000 women diagnosed with the condition every year. Unfortunately, this week an analysis of NHS England figures by Cancer Research UK has found that around 10,600 fewer women started treatment for breast cancer in 2020, compared to the…
Reforming Prostate Cancer Testing: Chris Hoy’s Urgent Appeal for Change
Olympic cyclist Sir Chris Hoy is advocating for improved prostate cancer tests for younger men following his terminal diagnosis in September 2023. His recent interview with the BBC reveals the limitations of the NHS’s current protocol for prostate cancer testing.
Government and Tech Innovators Unite to Advance Cancer Detection: The Potential of Pantum Detect
In a recent press release, the UK government outlined an initiative to boost tech deals aimed at further innovating cancer diagnosis in the country. This plan follows the Darzi review, which highlighted the critical state of the NHS, particularly the urgent need to improve cancer survival rates.
Darzi Report Findings: The Urgent Need for Innovative Technology in NHS Cancer Care
In the House of Commons, Health Secretary Wes Streeting introduced a "national mission" to tackle key health challenges. Presenting the Darzi report, commissioned by the Labour government, he outlined the NHS's ongoing struggles in the post-pandemic era, including missed targets in cancer care, A&E services, and hospital treatment.